Stockscreener 앱 받기
0.545
0.91%
-0.005
시간 외 거래:
.54
-0.005
-0.92%
전일 마감가:
$0.55
열려 있는:
$0.565
하루 거래량:
121.37K
Relative Volume:
0.36
시가총액:
$49.36M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-2.0605
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
-4.39%
1개월 성능:
+10.06%
6개월 성능:
-53.81%
1년 성능:
-53.42%
1일 변동 폭
$0.5368
$0.57
1주일 범위
$0.5368
$0.60
52주 변동 폭
$0.4679
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.545 | 49.36M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer - ACCESS Newswire
(ONC) Technical Data (ONC:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire UK
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
(ONC) Stock Trading Blueprint (ONC:CA) - news.stocktradersdaily.com
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics to Present New Pancreatic Cancer Data at Oncology Meeting Next Month - marketscreener.com
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at AS - GuruFocus
Oncolytics Biotech to Present Promising Pancreatic Cancer Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action - Barchart.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Developm - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Small-cap cancer therapy innovator raises $20M in flexible funding | 2025-04-11 | Investing News - Stockhouse
Oncolytics secures $20 million to advance cancer therapy development - The Pharma Letter
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. - GuruFocus
Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development - TipRanks
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital - Weekly Voice
Oncolytics Biotech® Inc. - MENAFN.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Stocks In Play: Oncolytics Biotech® Inc. - Barchart.com
Oncolytics Biotech’s Pelareorep Gains Attention at Key Oncology Event - TipRanks
Indo-Asian News Service - Indo-Asian News Service (IANS)
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):